Role of conventional cytogenetics in sequential karyotype analysis of myelodysplastic syndrome: a patient with der(1;7)(q10;p10)

França, Ivo Gabriel da Frota; Melo, M.; Teixeira, Manuela Soares Couto; Cordeiro, João Victor Alves; Borges, Daniela de Paula; Oliveira, Roberta Taiane Germano de; Furtado, Silvio Rocha; Magalhães, Sílvia Maria Meira; Pinheiro, Ronald Feitosa

doi:10.1016/j.htct.2018.05.009

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sequential cytogenetic analysis (both karyotyping and FISH) of follow-up samples has been established as identifying the possible clonal evolution of MDS clones leading to greater understanding of the heterogenous acquisition or loss of these genetic events in MDS [ 24 ]. Demonstrating an occurrence of clonal evolution and, to a lesser degree, the presence of subclones, at the time of diagnosis in patients with MDS, has an unfavorable influence on survival and AML progression.…”

Section: Cytogeneticsmentioning

confidence: 99%

Myelodysplastic Syndrome: Diagnosis and Screening

2022

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are heterogeneous groups of clonal myeloid disorders characterized by unexplained persistent peripheral blood (PB) cytopenia(s) of one or more of the hematopoietic lineages, or bone marrow (BM) morphologic dysplasia in hematopoietic cells, recurrent genetic abnormalities, and an increased risk of progression to acute myeloid leukemia (AML). In the past several years, diagnostic, prognostic, and therapeutic approaches have substantially improved with the development of Next Generation Sequencing (NGS) diagnostic testing and new medications. However, there is no single diagnostic parameter specific for MDS, and correlations with clinical information, and laboratory test findings are needed to reach the diagnosis.

show abstract

Section: Cytogeneticsmentioning

confidence: 99%

Myelodysplastic Syndrome: Diagnosis and Screening

2022

View full text Add to dashboard Cite

show abstract

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives

Zhang,

Deeb,

Deeb

et al. 2024

Cancers

View full text Add to dashboard Cite

Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes.

show abstract

Role of conventional cytogenetics in sequential karyotype analysis of myelodysplastic syndrome: a patient with der(1;7)(q10;p10)

Cited by 2 publications

References 23 publications

Myelodysplastic Syndrome: Diagnosis and Screening

Myelodysplastic Syndrome: Diagnosis and Screening

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives

Contact Info

Product

Resources

About